Frequently asked questions
COVID-19 has had a substantial impact on the market due to the outbreak of the COVID-19 pandemic. Since cancer treatment was delayed throughout the world after the onset of the pandemic, the demand for these drugs significantly declined.
North America accounted for the most heightened share in the global DNA repair drugs market.
There is an increase in cancer incidence worldwide; increasing Oncology R&D Expenditures etc., is driving the DNA repair drugs market.
The olaparib segment had a major share in the global market in 2022.
The ovarian cancer segment had a major share in the global market.
The hospital pharmacies segment had a major share in the global market.